Clinical trials: Advanced Intestinal Cancer
End of Life, Advanced Cancer
Engagement of Patients With Advanced Cancer
The Engagement of Patients with Advanced Cancer is an intervention that utilizes well-trained lay health coaches to engage patients and their families in goals of care and shared decision-making after a diagnosis of advanced…
- Conditions
- End of Life, Advanced Cancer, Lung Neoplasm, Gastric Cancer
- Trial name
- EPAC (NCT02966509)
- Testing
- EPAC
- Volunteers
- 213 people
- Sponsor
- Stanford University
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
111Indium-labelled IPN01087 (111In-IPN01087) is developed as a radioactive diagnostic imaging agent in patients with colorectal or pancreatic cancer.
- Trial name
- NCT04632199
- Testing
- 111In-IPN01087 Low dose, 111In-IPN01087 High dose
- Where
- 5 sites in Belgium, France
- Sponsor
- Ipsen
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
The primary objective of this trial is to explore the overall objective best response rate and the rate of non-progression at 16 weeks of sequential, alternating weekly administration of BIBF 1120 and BIBW 2992 in patients with…
- Trial name
- NCT00801294
- Testing
- BIBF 1120 and BIBW 2992
- Where
- 24 sites in France
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Colorectal Neoplasms, Neoplasms
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin].
- Trial name
- NCT00599924
- Testing
- sunitinib + FOLFOX
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Colorectal Cancer
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy
- Trial name
- NCT07722494
- Testing
- IBI363 + bevacizumab, Investigator's choice of therapy
- Where
- 2 sites in China
- Volunteers
- 550 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Recurrent Colon Cancer, Recurrent Rectal Cancer
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
This phase I/II trial is studying the side effects and best dose of sorafenib when given together with cetuximab and irinotecan and to see how well they work in treating patients with advanced or metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer
- Trial name
- NCT00134069
- Testing
- sorafenib tosylate, cetuximab, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Rectal Cancer
Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence
The purpose of this study is to identify the most promising treatment sequence in total neoadjuvant therapy for locally advanced rectal cancer with a high risk of recurrence.
- Trial name
- ICONA (NCT05054959)
- Testing
- Consolidation CAPOX Chemotherapy, Induction CAPOX Chemotherapy
- Where
- Slovenia
- Volunteers
- 62 people
- Sponsor
- Institute of Oncology Ljubljana
Oropharyngeal Cancer, Neck Cancer
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Background: Often, metastatic human papillomavirus (HPV) associated cancers cannot be cured. They also do not respond well to treatment. Some forms of colon cancer also have poor responses to treatment.
- Conditions
- Oropharyngeal Cancer, Neck Cancer, Human Papillomavirus, HPV
- Trial name
- NCT04708470
- Testing
- Bintrafusp Alfa, PDS01ADC, Entinostat
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Colorectal Cancer
Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer
This is a single-center, open-label, single-arm, exploratory phase II clinical trial designed to evaluate the preliminary efficacy and safety of sintilimab in combination with oral gossypol acetate in patients with advanced…
- Trial name
- NCT07656766
- Testing
- Sintilimab, Gossypol Acetate
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking University People's Hospital
Colorectal Cancer, Metastasis
PET-CT and Circulating Tumor Cells in Colorectal Cancer
The purpose of this study is to identify an early indicator of drug efficacy in patients with advanced colorectal cancer - a prospective evaluation of circulating tumor cells, positron-emission tomography scan and RECIST criteria.
- Trial name
- NCT01163305
- Testing
- Chemotherapy
- Where
- Hong Kong
- Volunteers
- 84 people
- Sponsor
- Chinese University of Hong Kong
Anal Cancer
A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma
SCARCE is a non-comparative randomized, 2:1 phase II study. The purpose of this study is to assess the progression-free survival rate at 12 months. (evaluation according with RECISTv1.1 criteria).
- Trial name
- SCARCE (NCT03519295)
- Testing
- MPDL3280A, mDCF
- Where
- 31 sites in France
- Volunteers
- 97 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colon Cancer, Neoadjuvant Therapies
Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial
Most colorectal cancers belong to the microsatellite stable (MSS) or proficient mismatch repair (pMMR) subtypes, with limited response to PD-1 inhibitors.
- Conditions
- Colon Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiation Therapy
- Trial name
- MODIFI-L (NCT07279077)
- Testing
- Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer
Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer
The purpose of this study is to evaluate the disease-free survival in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy with fluoropyrimidines and surgery followed by adjuvant combination…
- Trial name
- NCT00807911
- Testing
- Adjuvant FL, Adjuvant FOLFOX
- Where
- 6 sites in South Korea
- Volunteers
- 322 people
- Sponsor
- Asan Medical Center
Colonic Neoplasms
Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer
We plan to evaluate the efficacy and safety of cetuximab combined with anti-PD-1 and mFOLFOX6 in the treatment of RAS/BRAF WT locally advanced or metastatic right colon cancer
- Trial name
- CIFOXRC (NCT05468177)
- Testing
- neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Tongji Hospital
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Advanced Colorectal Cancer, Colorectal Cancer
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with…
- Trial name
- NCT00498407
- Testing
- CP-4055
- Where
- 4 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Clavis Pharma
Colorectal Cancer
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
This is a phase I/II multi-center open-label proof of concept study, consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of dacomitinib plus…
- Trial name
- M13DAP (NCT02039336)
- Testing
- Dacomitinib, PD-0325901, Docetaxel
- Where
- 3 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- The Netherlands Cancer Institute
Colorectal Carcinoma, Lynch Syndrome
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients
This study collects blood and stool samples from patients with suspected or diagnosed Lynch syndrome to evaluate a deoxyribonucleic acid (DNA) screening technique for the detection of colorectal cancer in Lynch syndrome patients.
- Trial name
- NCT05410977
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- 9 sites in United States
- Volunteers
- 950 people
- Sponsor
- Mayo Clinic
Rectal Cancer
Pre-op Rectal ChemoRad +/- Cetuximab
The purpose of this research study is to find out what effects (good and bad) cetuximab has on rectal cancer.
- Trial name
- NCT00527111
- Testing
- Cetuximab, 5-fluorouracil, Pelvic irradiation
- Where
- 41 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Oncology Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.